派斯林(600215.SH)與人工智能公司Mindtrace開展合作,在人工智能、視覺檢測、資產巡檢等製造領域推進全面協同
格隆匯3月13日丨派斯林(600215.SH)在投資者互動平臺表示,公司聚焦機器人自動化與智能製造,持續關注人工智能技術發展,加強科技創新。一方面充分利用在工業自動化領域積累的豐富技術數據和寶貴項目經驗,積極佈局人工智能與工業自動化深度融合,爲客戶提供更智能、更靈活的智能製造整體解決方案。另一方面,公司積極開展在人工智能領域的業務佈局,與人工智能公司Mindtrace開展合作,在人工智能、視覺檢測、資產巡檢等製造領域推進全面協同,深度融合人工智能與工業場景應用,不斷以AI賦能製造業高質量發展與轉型升級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.